Kyowa Kirin Co Ltd
TSE:4151
Kyowa Kirin Co Ltd
EPS (Diluted)
Kyowa Kirin Co Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kyowa Kirin Co Ltd
TSE:4151
|
EPS (Diluted)
¥113
|
CAGR 3-Years
5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
15%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
EPS (Diluted)
¥131
|
CAGR 3-Years
-22%
|
CAGR 5-Years
73%
|
CAGR 10-Years
7%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
EPS (Diluted)
¥155
|
CAGR 3-Years
65%
|
CAGR 5-Years
19%
|
CAGR 10-Years
-10%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
EPS (Diluted)
¥633
|
CAGR 3-Years
40%
|
CAGR 5-Years
22%
|
CAGR 10-Years
9%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
EPS (Diluted)
¥249
|
CAGR 3-Years
2%
|
CAGR 5-Years
19%
|
CAGR 10-Years
24%
|
|
|
Astellas Pharma Inc
TSE:4503
|
EPS (Diluted)
¥28
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-7%
|
|
Kyowa Kirin Co Ltd
Glance View
Kyowa Kirin Co., Ltd. stands as a notable presence in the global pharmaceutical landscape, having evolved from its roots in Japan into a significant force in medical innovation. This company, originally established from the merger of Kyowa Hakko Kogyo and Kirin Pharma, focuses on the development and commercialization of biopharmaceuticals that tackle complex medical conditions, primarily within the fields of oncology, nephrology, immunology, and neurology. With a strategy deeply rooted in research and development, Kyowa Kirin harnesses its proprietary antibody technologies and innovative approaches to deliver therapeutic solutions, fostering partnerships that expand its impact and reach. Their commitment to scientific progress is supplemented by a robust pipeline of investigational drugs, demonstrating their dedication to addressing unmet medical needs. Kyowa Kirin operates primarily on a business model that derives revenues from the successful commercialization of its pharmaceutical products. The company navigates the delicate balance between high-stakes investment in R&D and the potential high rewards that come from developing effective new treatments. By consistently bringing innovative therapies to market, they generate revenue through direct sales, collaborations, and licensing agreements within both domestic and international spheres. Additionally, their strategic alliances with biotech firms and research institutions globally enable them to enhance their R&D capabilities, ensuring a steady flow of new drugs that sustain their growth and solidify their competitive edge in the highly regulated and competitive pharmaceutical sector.
See Also
What is Kyowa Kirin Co Ltd's EPS (Diluted)?
EPS (Diluted)
113.1
JPY
Based on the financial report for Dec 31, 2024, Kyowa Kirin Co Ltd's EPS (Diluted) amounts to 113.1 JPY.
What is Kyowa Kirin Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
15%
Over the last year, the EPS (Diluted) growth was -25%. The average annual EPS (Diluted) growth rates for Kyowa Kirin Co Ltd have been 5% over the past three years , -2% over the past five years , and 15% over the past ten years .
You don't have any saved screeners yet